Abstract| Volume 51, SUPPLEMENT 1, S11, March 2015

Download started.


ITOC2 – 031. Immunomodulatory characteristics of Resminostat, a novel HDAC inhibitor in phase II clinical development

      This paper is only available as a PDF. To read, Please Download here.


      Anti-cancer effects of HDAC inhibitors were shown to rely on an intact immune system. Additionally, combination of HDAC inhibitors with different cancer immunotherapy approaches was shown to be successful, suggesting that HDAC inhibition itself may engage and mediate an anti-tumoural immune response during cancer therapy.


      Evaluation of immunomodulating effects of the HDAC inhibitor Resminostat, potentially contributing to its anti-tumoural activity.


      Resminostat effects on mechanisms affecting anti-tumoural immune responses were analysed in hepatocellular HepG2, Huh7, and SNU475 and adenocarcinomic A549 cells.


      Resminostat strongly reduced the expression of immunosuppression mediating enzymes, IDO1 and ARG1. Additionally, Resminostat considerably enhanced the expression of NKG2D ligands, MHC class I molecules, and several cancer testis antigens on several tumour cell lines. Interestingly, Resminostat was also able to up-regulate the expression of MHC class II and co-stimulatory molecule 4-1BBL.


      Resminostat showed promising immunomodulatory effects demonstrating potential synergism with immunotherapy approaches using opsonizing antibodies (e.g. rituximab), immunostimulating agents (e.g. cytokines, stimulating antibodies, TLR ligands), and immune checkpoint blockers (PD1/PDL1 and CTLA-4 inhibitors).
      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'


      Subscribe to European Journal of Cancer
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect